SCHEMBL15077845

SCHEMBL15077845

[2H]C([2H])(c1ccnc(NC(=O)OC(C)(C)C)c1)N1CCc2c(NC(=O)Nc3cc(Cl)ccc3C)cccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.43
MAPT P10636 4/20 0.37
GAA P10253 2/20 0.37
TP53 P04637 1/20 0.37
EPHB4 P54760 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
CYP2C9 P11712 1/20 0.36
PTGER1 P34995 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
POLB P06746 1/20 0.36
IDH2 P48735 1/20 0.36
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
P2RX3 P56373 1/20 0.35
CDK5 Q00535 1/20 0.35
DYRK1A Q13627 1/20 0.35
CDK5R1 Q15078 1/20 0.35
ATM Q13315 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15077850 0.90 CCR2 (0.41) CCR2MAPTEPHB4CYP2C9PTGER1
SCHEMBL15077844 0.84 MAPT (0.41) MAPTGAATP53EPHB4TRPV1
SCHEMBL15077846 0.81 CCR2 (0.42) CCR2MAPTGAATP53EPHB4
SCHEMBL167233 0.76 ALDH1A1 (0.47) MAPTGAAEPHB4POLBMEN1
SCHEMBL165141 0.75 ALDH1A1 (0.42) MAPTGAAEPHB4POLBMEN1
SCHEMBL29442824 0.68 CCR2 (0.50) CCR2CYP2C9PTGER1P2RX3LMNA
SCHEMBL29358615 0.68 CCR2 (0.50) CCR2CYP2C9PTGER1P2RX3LMNA
SCHEMBL21394568 0.68 CCR2 (0.50) CCR2CYP2C9PTGER1P2RX3LMNA
SCHEMBL166071 0.68 ALDH1A1 (0.42) MAPTGAATP53EPHB4POLB
SCHEMBL15054097 0.67 BRAF (0.38) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 CCR2 2830/4885MAPT 1276/4885GAA 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.